First Name: Robert  
Last Name: Griffith  
Institution: University of Miami Miller School of Medicine  
Address 1: 10 Aragon Ave.  
Address 2: #918  
City: Miami  
State/Province: FL  
Country: USA  
Zip: 33134  
Phone: 865-235-7149  
Alternate Phone: 865-546-4814  
Email: r.griffith@med.miami.edu

Requirements to submit AOI:

A comprehensive review of previously published data has been completed.: Yes
The specific aims are clear and focused.: Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.: Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months.: Yes

Project Title: Changing Patterns of Non-Melanoma Skin Cancer in Childhood Cancer Survivors Who Received Radiation Therapy
Planned research population (eligibility criteria): Individuals who have received radiation therapy for cancer in childhood with a documented/confirmed subsequent non-melanoma skin cancer. This will include individuals from both the initial and expanded cohorts.
Proposed specific aims: 1. Describe cumulative incidence, risk and risk factors for development of NMSC in survivors in the expanded cohort who received radiation therapy 2. Compare expanded cohort data with previously described data from the initial cohort and identify if changes in radiation therapy technique have influenced the development of NMSC in childhood cancer survivors who received radiotherapy 3. Compare expanded cohort data with previously described data from the initial cohort and identify if changes in radiation therapy technique the time to development of NMSC in childhood cancer survivors who received radiotherapy 4. Quantify the association of cumulative dose of ionizing radiation and the risk of NMSC in childhood cancer survivors using data from both cohorts
Will the project require non-CCSS funding to complete?: No
If yes, what would be the anticipated source(s) and timeline(s) for securing funding?:

Does this project require contact of CCSS study subjects for . . .

Additional self-reported information: No
Biological Samples: No
Medical record data: No
If yes to any of the above, please briefly describe:

What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy: Primary
Chronic Disease:
Psychology / Neuropsychology:
Genetics:
Cancer Control:
Epidemiology / Biostatistics: Secondary

To describe the anticipated scope of the study, please indicate the specific CCSS data to be included as outcome (primary or secondary) or correlative factors. (Check all that apply)

Late mortality:
Second Malignancy: Primary

Health Behaviors

Tobacco:
Alcohol:
Physical activity:
Medical screening: Correlative Factors
Other:
If other, please specify:

Psychosocial

Insurance:
Marriage:
Education:
Employment:
Other:
If other, please specify:

Medical conditions

Hearing/Vision/Speech:
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system:
Other:
If other, please specify:

<table>
<thead>
<tr>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe medications:</td>
</tr>
</tbody>
</table>

| Pregnancy and offspring: |
| Family History: |

| Psychologic/Quality of Life |
| BSI-18: |
| SF-36: |
| CCSS-NCQ: |
| PTS: |
| PTG: |
| Other: |
| If other, please specify: |

| Chronic conditions (CTCAE v3): |
| Health status: |

| Demographic |
| Age: Correlative Factors |
| Race: Correlative Factors |
| Sex: Correlative Factors |
| Others: |
| If others, please specify: |

| Cancer treatment |
| Chemotherapy: Correlative Factors |
| Radiation therapy: Correlative Factors |
| Surgery: Correlative Factors |

| Anticipated sources of statistical support |
| CCSS Statistical Center: Yes |
| Local institutional statistician: |
If local, please provide the name(s) and contact information of the statistician(s) to be involved.: 
Will this project utilize CCSS biologic samples?: No 

If yes, which of the following? 

Buccal cell DNA: 
Peripheral blood: 
Lymphoblastoid cell lines: 
Second malignancy pathology samples: 
Other requiring collection of samples: 
If other, please explain: 

Other general comments: